Periodontal Therapy in Coronary Artery Patients

Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01609725

Acronym

PerioCardio

Enrollment

Registered

2012-06-01

Start date

2012-01-31

Completion date

2017-12-31

Last updated

2019-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atheroma, Cardiovascular Diseases, Coronary Artery Disease

Keywords

Coronary artery disease, C reactive protein, Periodontitis, Periodontal therapy, Flow-mediated dilation

Brief summary

Gingival inflammation has been associated with cardiovascular diseases, including heart attack and stroke, because of elevation of blood risk markers such as cholesterol, glucose and C reactive protein. The treatment of gingival diseases decreases the concentration of these risk factors in the blood of cardiovascular patients.

Interventions

DEVICESubgingival scaling and root planing

Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia

DEVICEOral prophylaxis

One session of supraginigval calculus removal

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

* 35 years and older * coronary artery disease * more than 10 teeth * chronic periodontitis defined as 2 non-adjacent teeth with probing depth 5+mm and periodontal attachment loss 4+mm

Exclusion criteria

* use of antibiotics in the last 6 months * periodontal therapy in the last 12 months

Design outcomes

Primary

Measure	Time frame
Changes in C reactive protein	Baseline, 3, 6 and 12 months
Changes in flow-mediated dilation	Baseline, 1, 3 and 6 months

Secondary

Measure	Time frame
Changes in Interleukin 8	Baseline, 3, 6, 12 months
Changes in Interleukin 6	Baseline, 3, 6, 12 months
Changes in Cholesterol	Baseline, 3, 6, 12 months
Changes in Interleukin 1B concentrations	Baseline, 3, 6, 12 months
Changes in LDL/HDL	Baseline, 3, 6, 12 months
Changes in Fibrinogen	Baseline, 3, 6, 12 months
Changes in Glycated hemoglobin	Baseline, 3, 6, 12 months
Changes in TNF alpha	Baseline, 3, 6, 12 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026